Cannabis and the Heart

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Cannabis has real, measurable effects on the cardiovascular system, and its growing legality and social acceptance are not statements about its safety for the heart. The active compound, THC, activates the sympathetic nervous system, acutely raising heart rate, myocardial oxygen demand, and blood pressure, and increasing platelet activation — effects that are well established.¹ These acute changes can matter: the risk of a heart attack is transiently elevated in the hour after smoking cannabis, and in people with existing angina, cannabis lowers the threshold at which chest pain appears during exertion.²,³ Beyond the acute effects, a growing body of observational research links cannabis use to higher rates of heart attack, stroke, and cardiovascular death — associations that in some studies persist among people who have never smoked tobacco and increase with heavier use, though the findings are not uniform, the evidence is observational, and it cannot yet establish that cannabis causes these events.¹,⁴,⁶ The form matters too: smoked cannabis adds the harms of combustion, while edibles carry their own risks from delayed, prolonged, and sometimes excessive dosing. The honest summary is that the acute cardiovascular effects are clear, the long-term outcome evidence is real but still evolving, and cannabis has no documented cardiovascular benefit. This article explains what is known, what remains uncertain, and what it means — particularly for people who already have cardiovascular disease.

“Legal” and “Natural” Are Not “Safe for the Heart”

The previous article examined the products people use in place of cigarettes. This one turns to a substance increasingly used alongside or instead of them, and increasingly legal: cannabis. As legalization has spread and acceptance has grown, many people have come to regard it as harmless — a natural product, sanctioned by law, without the stigma of cigarettes. But legality is a regulatory decision and acceptance a cultural one; neither says anything about what cannabis does to the heart and blood vessels.

Looking directly at the evidence, the cardiovascular picture has two distinct parts. The first is what cannabis does in the short term — its acute physiological effects — which are well established. The second is whether it raises the risk of hard outcomes like heart attack and stroke over time, where the evidence is real and growing but still largely observational and evolving. Treating either as the whole story — dismissing the outcome concerns as unproven, or the acute effects as proof of long-term harm — misrepresents what is known. The most useful way to hold this article in mind: the strongest evidence concerns what cannabis does immediately, while the greatest uncertainty concerns what repeated exposure means over decades.

This is the eighth article in the series. It follows the article on vaping and other tobacco products and precedes the article on recovering from a lapse. As with vaping, the appropriate stance is evidence-loyal rather than tribal: cannabis is neither the harmless plant of its advocates nor a proven cardiovascular poison, and the accurate picture lies in what the data actually show.

Why Cardiologists Are Paying More Attention

For years, cannabis received relatively little attention in cardiovascular medicine, because use was less common and high-quality outcome data were scarce. That has changed. Legalization has expanded, cannabis products have become substantially more potent — the THC concentration of typical products today is several-fold higher than it was decades ago⁷ — and use has grown across all ages, including among older adults, who are the group most likely to already have cardiovascular disease.¹ More people with hearts at risk are now using a stronger product than the one most older studies measured. The current evidence justifies neither reassurance nor alarm; it justifies careful study and honest discussion between patients and their clinicians.

How Cannabis Affects the Cardiovascular System

The acute cardiovascular effects of cannabis are among the best-established facts in this article, because they follow directly from how THC acts on the body.

THC — delta-9-tetrahydrocannabinol, the main psychoactive compound in cannabis — acts on cannabinoid receptors that are found not only in the brain but in the heart muscle, the blood vessels, and on platelets.¹ Through these receptors, THC stimulates the sympathetic nervous system — the “fight or flight” system — while suppressing the opposing parasympathetic system. The cardiovascular consequences are predictable: heart rate rises, often substantially; the heart’s demand for oxygen increases; blood pressure rises acutely; and platelets, the cells involved in clotting, become more activated.¹ Cannabis can also acutely provoke rhythm disturbances, including extra beats and, in some cases, atrial fibrillation.¹

Each of these effects has a plausible route to harm. A faster heart rate combined with higher blood pressure raises the work the heart must do and the oxygen it requires, at the same time as it may reduce the supply — a combination that is dangerous in an artery already narrowed by plaque. Increased platelet activation is relevant to the clot formation that triggers most heart attacks. None of this proves that cannabis causes cardiovascular events in a given person, but it explains why the outcome associations discussed below are biologically credible rather than random. Importantly, these acute effects are driven by THC itself and therefore occur regardless of how the cannabis is taken — smoked, vaped, or eaten. CBD (cannabidiol), the other major cannabinoid, is non-intoxicating and does not drive the same sympathetic activation as THC; it is far less studied cardiovascularly and, like THC, can interact with medications. Despite widespread marketing claims, there is currently no high-quality clinical evidence that CBD improves cardiovascular outcomes.

What the Evidence Suggests About Heart Attack and Stroke

The question that matters most is whether these acute effects translate into real cardiovascular events. Here the evidence is genuinely informative but must be read carefully.

The clearest signal concerns the period immediately after use. In a study of nearly 4,000 heart attack patients, the risk of a heart attack was 4.8 times higher in the hour after smoking cannabis than at other times, and by the second hour that elevation had largely subsided.² This pattern — a sharp, transient spike in risk that fades within hours — fits the acute physiology precisely: the surge in heart rate, blood pressure, oxygen demand, and platelet activation creates a brief window of heightened vulnerability. It is the cannabis equivalent of the well-recognized triggering of heart attacks by sudden physical or emotional stress. (The estimate rests on a small number of exposed patients, which is why it is best read as consistent with the physiology rather than as a precise figure.)

Beyond the acute window, a growing body of research links regular cannabis use to higher rates of cardiovascular events. In a large study of more than 430,000 US adults, daily cannabis use was associated with roughly 25% higher odds of heart attack and 42% higher odds of stroke, after accounting for tobacco use, age, diabetes, and other factors — with heavier use associated with higher odds in a dose-dependent pattern.⁴ A 2025 systematic review and meta-analysis pooling real-world data reached broadly similar conclusions, associating cannabis use with acute coronary syndrome (about 29% higher risk), stroke (about 20% higher), and cardiovascular death (roughly doubled) — although the same analysis found no significant association for a combined coronary-and-stroke outcome, which illustrates how heterogeneous the underlying data are.⁶ Cannabis use has also been associated, across observational studies, with atrial fibrillation, heart failure, and sudden cardiac death.¹

Two features of this evidence make it harder to dismiss than it once was. First, in the large US study the associations held among people who had never smoked tobacco, which addresses the longstanding concern that cannabis findings simply reflect the tobacco that cannabis users often also smoke.⁴ Second, the relationship was dose-dependent, with more frequent use linked to higher risk — a pattern that, while not proof, is one of the features that strengthens a causal interpretation.⁴ The overall picture is of a real and growing signal that is nonetheless not uniform across studies.

A distinction runs through all of this and is worth making explicit. Cannabis appears capable of acting as an acute trigger for cardiovascular events in susceptible people — much as vigorous exertion or intense emotional stress can trigger an event in someone with underlying coronary disease.² Whether long-term cannabis use independently accelerates atherosclerosis — the slow, cumulative plaque formation described in Article 1 — is a separate and much less certain question. Most of the strongest evidence concerns triggering; the chronic-disease question remains genuinely open.

Why the Evidence Is Still Evolving

Honesty about the strength of this evidence is not a weakness in the argument; it is the argument. The outcome data on cannabis and cardiovascular disease are suggestive, not conclusive, for several concrete reasons.

Most of the evidence is observational, and much of it is cross-sectional — meaning it captures cannabis use and cardiovascular disease at the same point in time and cannot establish which came first, let alone that one caused the other.⁴ Randomized trials, which could establish causation, are largely absent and are difficult to conduct for a substance used at varying doses and potencies over years. The studies are complicated by confounding: cannabis users differ from non-users in many ways beyond cannabis, and although good studies adjust for tobacco and other factors, no adjustment is perfect. The findings are also not uniform — while several analyses report significant associations, others, and even parts of the same meta-analyses, do not reach significance, and exposure is measured inconsistently across studies, from ever-use to daily use, with no standard for dose or potency.⁶ Much of the earlier research was conducted in younger populations, in whom cardiovascular events are rare, limiting what can be concluded about older adults. And cannabis itself has changed — the THC potency of modern products is far higher than that of decades past, so older data may understate current risks. Reflecting all of this, the American Heart Association’s assessment is that safety signals have emerged linking cannabis to adverse cardiovascular outcomes, but that rigorously designed prospective studies are still needed to define the risk.¹

This is the accurate epistemic position: the acute cardiovascular effects are established, the outcome associations are real and increasingly reported, and the causal question is not yet settled. A reader deciding about cannabis should weigh a credible and growing signal of harm — not a proven one, and not a clean bill of health either.

There is also a matter of absolute risk worth stating. A given relative increase — the 25% higher odds of heart attack seen with daily use, for instance — can represent a very different absolute increase depending on a person’s baseline cardiovascular risk. For a young person with no risk factors, even a meaningfully higher relative risk sits on a low baseline, so the absolute chance of an event remains small. For an older person, or one who already has cardiovascular disease, the same relative increase translates into a larger and more consequential absolute risk. This is why the considerations for people with existing heart disease, discussed below, are the sharpest part of the picture.

How the Form Matters

Cannabis is smoked, vaped, and eaten, and the route changes part — but not all — of the cardiovascular picture.

Smoked cannabis carries the harms of combustion on top of the effects of THC. As Article 1 and Article 7 established, burning any plant material produces carbon monoxide, oxidizing chemicals, and fine particulates, and cannabis smoke contains many of the same categories of harmful combustion products as tobacco smoke.¹ A person who smokes cannabis is therefore exposed both to THC’s cardiovascular effects and to combustion products that independently damage the vascular system. For this reason, the American Heart Association advises against smoking or vaping any substance, including cannabis, because of the harm inhaled combustion and aerosol products can do to the heart, lungs, and blood vessels.¹

Edibles avoid combustion, but they are not free of cardiovascular concern: avoiding combustion removes one source of harm but not THC’s cardiovascular effects. Because THC taken by mouth is absorbed more slowly and its effects are delayed and prolonged, people sometimes take additional doses before the first has taken effect, leading to unexpectedly high exposure. Partly for this reason, edible cannabis appears more likely than smoked cannabis to produce adverse effects — cardiovascular and psychiatric — severe enough to prompt emergency care.¹ The route, in other words, shifts the risk profile: smoking adds combustion harm, while edibles add the hazard of delayed, unpredictable, and sometimes excessive dosing. What no route removes is the underlying cardiovascular effect of THC itself.

Cannabis and People Who Already Have Cardiovascular Disease

For readers who already have cardiovascular disease or significant risk factors, cannabis warrants particular caution, and this is where the evidence is most directly actionable.

The reason is mechanistic and specific. In people with coronary artery disease, the heart’s blood supply is already limited by narrowed arteries. Cannabis raises heart rate, blood pressure, and myocardial oxygen demand at the same time — precisely the combination that provokes angina and ischemia in a compromised circulation. This is not theoretical: in a classic controlled study of patients with stable angina, smoking cannabis reduced the time they could exercise before chest pain appeared by roughly half, about 48%,³ a larger effect than that of a high-nicotine cigarette.⁵ For someone with established coronary disease, a recent heart attack, an arrhythmia, or heart failure, the acute effects of cannabis are not a neutral event.

There is a second, less obvious concern for this group: drug interactions. Cannabinoids are processed by the same liver enzyme systems that metabolize many cardiovascular medications, and cannabis can therefore alter the levels and effects of drugs including certain blood thinners, statins, and heart-rhythm medications.¹ Warfarin is a concrete example: because cannabinoids inhibit the liver enzymes that clear it, cannabis use can raise warfarin levels and bleeding risk.¹ For a patient taking these medications, cannabis is not only a direct cardiovascular stimulant but a potential source of interactions that can make prescribed therapy less effective or less safe. This is a specific, concrete reason that cannabis use belongs in the conversation with a cardiology team rather than kept separate from it.

The practical implication is not a moral judgment but a clinical one: for a person with cardiovascular disease, cannabis carries risks that a healthy person does not face to the same degree, and those risks are worth understanding and discussing openly with the clinicians managing their care.

Common Beliefs vs What the Evidence Shows

Several widely held beliefs about cannabis do not survive contact with the cardiovascular evidence.

What This Means

The practical implications follow from separating what is established from what is still emerging. Cannabis has clear acute cardiovascular effects and no documented cardiovascular benefit; the outcome evidence linking it to heart attack, stroke, and cardiovascular death is a real and growing signal, but an observational and heterogeneous one that cannot yet establish causation. That combination calls for informed caution rather than either alarm or dismissal — and for particular care in the people most exposed to the downside: those who already have cardiovascular disease.

What This Means for You

• Do not treat “legal” or “natural” as “safe.” Cannabis has real acute cardiovascular effects; its legal status and reputation say nothing about its effect on the heart.¹
• Weigh the outcome evidence honestly. The link to heart attack, stroke, and cardiovascular death is a credible and growing signal — strengthened by its dose-response pattern and its persistence in some never-tobacco-smokers — but it is not proven causation. That is a reason for informed caution, not panic, and not dismissal.⁴,⁶
• Avoid smoking or vaping cannabis. Inhaling combustion or aerosol products adds vascular harm on top of THC’s effects; this is the clearest route-specific point the evidence supports.¹
• If you have cardiovascular disease or its risk factors, be especially cautious and open with your clinician.Cannabis lowers the angina threshold, stresses a compromised circulation, and interacts with common cardiovascular medications; disclosing use to your care team is necessary information for safe treatment, not a matter of judgment.¹,³
• Expect the evidence to sharpen. As legalization spreads and better studies are conducted, the picture will clarify; for now, cannabis has no documented cardiovascular benefit and a real, if not fully quantified, cardiovascular risk.⁶

One caution specific to cannabis: because it causes a racing heart and can produce chest discomfort of its own, cardiac symptoms after use are easy to dismiss as “just the high.” They should not be — chest pain, pressure, or breathlessness after using cannabis warrants prompt medical evaluation.

How Strong Is the Evidence?

Not all of the conclusions in this article rest on equally certain evidence, and knowing the difference is part of using it well. The table below summarizes how confident the current evidence is in each main conclusion.

Clinical Bottom Line

Cannabis has clear, well-established acute cardiovascular effects: through THC, it raises heart rate, blood pressure, and myocardial oxygen demand and activates platelets, and the risk of a heart attack is transiently elevated in the hour after smoking.¹,² Beyond these acute effects, a growing body of observational evidence links cannabis use to higher rates of heart attack, stroke, and cardiovascular death — associations that in some studies persist among never-tobacco-smokers and rise with heavier use, but that remain observational and heterogeneous and cannot yet establish causation.⁴,⁶ Smoking cannabis adds the harms of combustion, and the effects are most consequential for people who already have cardiovascular disease, in whom cannabis lowers the angina threshold and interacts with cardiac medications.¹,³ Legality and social acceptance do not make cannabis safe for the heart; it has no documented cardiovascular benefit, a credible and evolving signal of harm, and specific risks for those with existing disease — which makes honest discussion with a clinician, rather than silence, the sensible course.

What Comes Next

This article covered cannabis; the next returns to the process of quitting smoking. Article 9 addresses what happens after a lapse — why returning to smoking after a period of abstinence is common and not a sign of failure, what distinguishes a single slip from a full relapse, and how to recover and try again, using what the attempt revealed to make the next one more likely to succeed.

Key Terms

Cannabinoid receptors: Receptors (including CB1) that THC acts on, located not only in the brain but in the heart muscle, blood vessels, and platelets, explaining cannabis’s cardiovascular effects.

CBD (cannabidiol): A non-intoxicating cannabinoid that does not drive the acute sympathetic cardiovascular effects of THC; less studied, and able to interact with medications.

Cross-sectional study: A study that measures exposure and outcome at the same point in time; it can reveal associations but cannot establish which came first or whether one caused the other.

Myocardial oxygen demand: The amount of oxygen the heart muscle requires; raised by increases in heart rate and blood pressure, and dangerous when the supply is limited by narrowed arteries.

Angina threshold: The level of exertion at which chest pain from inadequate blood supply appears; lowered by cannabis, meaning symptoms occur at less exertion.

THC (delta-9-tetrahydrocannabinol): The main psychoactive compound in cannabis, responsible for its acute cardiovascular effects regardless of how it is consumed.

Sympathetic nervous system: The “fight or flight” system that THC stimulates, driving the acute rise in heart rate, blood pressure, and myocardial oxygen demand.

References

1. Page RL 2nd, Allen LA, Kloner RA, et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2020;142(10):e131–e152. https://doi.org/10.1161/CIR.0000000000000883
2. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–2809. https://doi.org/10.1161/01.CIR.103.23.2805
3. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med.1974;291(2):65–67. https://doi.org/10.1056/NEJM197407112910203
4. Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13(5):e030178. https://doi.org/10.1161/JAHA.123.030178
5. Aronow WS, Cassidy J. Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin Pharmacol Ther. 1975;17(5):549–554. https://doi.org/10.1002/cpt1975175549
6. Storck W, Elbaz M, Vindis C, Déguilhem A, Lapeyre-Mestre M, Jouanjus E. Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. 2025;111(22):1047–1056. https://doi.org/10.1136/heartjnl-2024-325429
7. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–619. https://doi.org/10.1016/j.biopsych.2016.01.004

HeartBuddi® • Your heart. Own it.